FDA Often Looks Outside The Application, Review Documents Show
This article was originally published in Pharmaceutical Approvals Monthly
A look back at the past year of Pharmaceutical Approvals Monthly’s Drug Review Profile series illustrates the many ways FDA takes external factors into consideration when reviewing an application – from guiding trials to look for certain class safety signals to finding support for a particular endpoint.
You may also be interested in...
Regulators approved the PET imaging agent for estimating neuritic plaque density in the brain despite the apparent limited clinical utility of the class.
AstraZeneca’s SGLT-2 inhibitor Farxiga (dapagliflozin) finally clears FDA, and without a black box warning on bladder cancer risk – allowing the drug to compete with J&J’s first-to-market Invokana.
FDA’s top cancer drug reviewer has taken to the podium to paint a picture of the next phase in cancer drug development, which includes new business models, a return to single-arm trials and a new emphasis on safety.